1. |
Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China[J]. N Engl J Med, 2010, 362(12): 1090-1101. DOI: 10.1056/NEJMoa0908292.
|
2. |
Li Y, Teng D, Shi X, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study[J/OL]. BMJ, 2020, 369: m997[2020-04-28]. https://pubmed.ncbi.nlm.nih.gov/32345662/. DOI: 10.1136/bmj.m997.
|
3. |
Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults[J]. JAMA, 2013, 310(9): 948-959. DOI: 10.1001/jama.2013.168118.
|
4. |
Wang L, Gao P, Zhang M, et al. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013[J]. JAMA, 2017, 317(24): 2515-2523. DOI: 10.1001/jama.2017.7596.
|
5. |
Yang QH, Zhang Y, Zhang XM, et al. Prevalence of diabetic retinopathy, proliferative diabetic retinopathy and non-proliferative diabetic retinopathy in Asian T2DM patients: a systematic review and meta-analysis[J]. Int J Ophthalmol, 2019, 12(2): 302-311. DOI: 10.18240/ijo.2019.02.19.
|
6. |
Tan GS, Gan A, Sabanayagam C, et al. Ethnic differences in the prevalence and risk factors of diabetic retinopathy: the Singapore epidemiology of eye diseases study[J]. Ophthalmology, 2018, 125(4): 529-536. DOI: 10.1016/j.ophtha.2017.10.026.
|
7. |
Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy[J]. Diabetes Care, 2012, 35(3): 556-564. DOI: 10.2337/dc11-1909.
|
8. |
Bandello F, Cicinelli MV. 19th EURETINA congress keynote lecture: diabetic retinopathy today[J]. Ophthalmologica, 2020, 243(3): 163-171. DOI: 10.1159/000506312.
|
9. |
Nawaz IM, Rezzola S, Cancarini A, et al. Human vitreous in proliferative diabetic retinopathy: characterization and translational implications[J/OL]. Prog Retin Eye Res, 2019, 72: 100756[2019-04-02]. https://pubmed.ncbi.nlm.nih.gov/30951889/. DOI: 10.1016/j.preteyeres.2019.03.002.
|
10. |
Staurenghi G, Feltgen N, Arnold JJ, et al. Impact of baseline diabetic retinopathy severity scale scores on visual outcomes in the VIVID-DME and VISTA-DME studies[J]. Br J Ophthalmol, 2018, 102(7): 954-958. DOI: 10.1136/bjophthalmol-2017-310664.
|
11. |
Zhang J, Strauss EC. Sensitive detection of therapeutic efficacy with the ETDRS diabetic retinopathy severity scale[J]. Clin Ophthalmol, 2020, 14: 4385-4393. DOI: 10.2147/OPTH.S286527.
|
12. |
Ip MS, Zhang J, Ehrlich JS. The clinical importance of changes in diabetic retinopathy severity score[J]. Ophthalmology, 2017, 124(5): 596-603. DOI: 10.1016/j.ophtha.2017.01.003.
|
13. |
Singer M, Liu M, Schlottmann PG, et al. Predictors of early diabetic retinopathy regression with ranibizumab in the RIDE and RISE clinical trials[J]. Clin Ophthalmol, 2020, 14: 1629-1639. DOI: 10.2147/OPTH.S247061.
|
14. |
Moshfeghi A, Garmo V, Sheinson D, et al. Five-year patterns of diabetic retinopathy progression in US clinical practice[J]. Clin Ophthalmol, 2020, 14: 3651-3659. DOI: 10.2147/OPTH.S275968.
|
15. |
Lee SJ, Shin IC, Jeong IW, et al. Prospective, single-center, six-month study of intravitreal ranibizumab for macular edema with nonproliferative diabetic retinopathy: effects on microaneurysm turnover and non-perfused retinal area[J]. Clin Ophthalmol, 2020, 14: 1609-1618. DOI: 10.2147/OPTH.S248529.
|
16. |
Pappuru RKR, Ribeiro L, Lobo C, et al. Microaneurysm turnover is a predictor of diabetic retinopathy progression[J]. Br J Ophthalmol, 2019, 103(2): 222-226. DOI: 10.1136/bjophthalmol-2018-311887.
|
17. |
Bonnin S, Dupas B, Lavia C, et al. Anti-vascular endothelial growth factor therapy can improve diabetic retinopathy score without change in retinal perfusion[J]. Retina, 2019, 39(3): 426-434. DOI: 10.1097/IAE.0000000000002422.
|
18. |
Reddy RK, Pieramici DJ, Gune S, et al. Efficacy of ranibizumab in eyes with diabetic macular edema and macular nonperfusion in RIDE and RISE[J]. Ophthalmology, 2018, 125(10): 1568-1574. DOI: 10.1016/j.ophtha.2018.04.002.
|
19. |
Chandra S, Sheth J, Anantharaman G, et al. Ranibizumab-induced retinal reperfusion and regression of neovascularization in diabetic retinopathy: an angiographic illustration[J]. Am J Ophthalmol Case Rep, 2018, 9: 41-44. DOI: 10.1016/j.ajoc.2018.01.006.
|
20. |
Tadayoni R. Time to call into question the fundus-based evaluation of diabetic retinopathy after intravitreal injections[J]. J Ophthalmic Vis Res, 2020, 15(1): 4-6. DOI: 10.18502/jovr.v15i1.5971.
|
21. |
Flaxel CJ, Adelman RA, Bailey ST, et al. Diabetic retinopathy preferred practice pattern®[J]. Ophthalmology, 2020, 127(1): 66-145. DOI: 10.1016/j.ophtha.2019.09.025.
|